The Dipeptidyl Peptidase 9 (Dpp9) enzyme, a member of the serine protease family, represents a largely uncharted territory within cellular biochemistry. While its structural homology to other dipeptidyl peptidases suggests potential roles in peptide processing, its precise functions and substrates remain elusive. This proposal outlines a research plan designed to systematically investigate the enzymatic activity of Dpp9 and to identify its physiological substrates, thereby elucidating its contribution to cellular pathways and assessing its potential as a therapeutic target. Initial hypotheses propose that Dpp9 plays a critical role in modulating signaling pathways through the cleavage of specific peptide mediators, and that dysregulation of this activity may be implicated in disease states.
The first phase of this research will focus on characterizing the enzymatic properties of purified recombinant Dpp9. Using a panel of synthetic peptide substrates with varying sequences and cleavage sites, we will determine Dpp9's substrate specificity and kinetic parameters (Km and kcat). This will involve spectrophotometric assays measuring the release of chromogenic or fluorogenic leaving groups. Further, we will explore the enzyme's dependence on pH, temperature, and potential cofactor requirements. Understanding these fundamental enzymatic characteristics is crucial for predicting its in vivo function. For instance, if Dpp9 exhibits a preference for substrates involved in inflammatory signaling, this would strongly suggest a role in immune responses.
Following the in vitro characterization, the subsequent phase will employ proteomic approaches to identify endogenous Dpp9 substrates within relevant cellular models. We propose using a combination of affinity purification coupled with mass spectrometry (AP-MS). Cells or tissue lysates will be treated with a chemical crosslinker to stabilize enzyme-substrate interactions, followed by immunoprecipitation using an antibody specific to Dpp9. Proteins co-precipitated with Dpp9 will then be identified and quantified by LC-MS/MS. This technique allows for the unbiased discovery of potential substrates in their native cellular context. Identifying peptides that are consistently depleted or altered in the presence of Dpp9 activity would provide strong evidence for its role as a processing enzyme. For example, if peptides derived from a known growth factor are found to be rapidly degraded in cells expressing active Dpp9, this would implicate the enzyme in growth factor homeostasis.
The final phase will investigate the physiological relevance of identified Dpp9 substrates and its potential involvement in disease pathology. This will involve gene silencing or overexpression studies of Dpp9 in cell culture models relevant to conditions where peptide signaling is known to be altered, such as certain autoimmune diseases or neurodegenerative disorders. We will assess the impact on downstream signaling pathways and cellular phenotypes. For instance, if Dpp9 cleaves an inhibitory peptide that normally limits T-cell activation, then increased Dpp9 activity could lead to hyperinflammation. Conversely, if Dpp9 cleaves a pro-apoptotic peptide, its inhibition might be protective. Furthermore, analysis of Dpp9 expression levels and localization in patient-derived tissues or biofluids could provide correlative evidence for its involvement in disease.
In conclusion, this research proposal outlines a comprehensive strategy to systematically define the enzymatic activity, substrate repertoire, and physiological significance of the Dpp9 enzyme. By combining biochemical characterization, proteomic identification, and functional studies, we aim to move beyond speculation and establish a firm understanding of Dpp9's role in cellular processes. The successful identification of Dpp9's substrates and pathways will not only advance fundamental knowledge in biochemistry but may also pave the way for novel therapeutic interventions targeting diseases where aberrant peptide signaling is a contributing factor.